// App-Quantinova.ai

PO‐067 : Positive benefits of changing from intravenous Rituximab administration to subcutaneousadministration: a single centre experience

Researchers

Presenter

  • S Irwin

Principal Investigators

  • C Rowntree

  • H Cosh

  • C Bloodworth

Medical Centers

  • Dept. of Haematology, University Hospital of Wales, Cardiff, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • DNA Damage Inducible Transcript 3

Drug/Treatment

  • Bendamustine

  • Rituximab

Outcome

  • N/A

Study Design

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved